Latest News

Germany to pump €1bn into breakthrough innovation

German Research Minister Anja Karliczek and Economics Minister Peter Altmaier make a joint statement on the founding of the Agency for Jump Innovations following the meeting of the Federal Cabinet. © BMBF / Hans-Joachim Rickel


by tg

Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be funded with roughly €1bn over 10 years.

The move is intented to keep value creation in Germany.  The idea for such an agency is lent from the US agency DARPA (Defense Advanced Research Projects Agency), which was founded by President Dwight D. Eisenhower in the 1950ies to support commercialisation of groundbreaking inventions such as the Internet, GPS or driverless vehicles. Besides Germany, Sweden and Switzerland have already established innovation agencies for non-military purposes. 

The German agency is set to start next year. According to Germany’s minister for economics, Peter Altmaier, a first call will seek for 3 to 4 promising artificial intelligence projects.

CRISPR Therapeutics and Viacyte launch diabetes partnership

Under the agreement CRISPR Therapeutics AG will use ViaCyte Inc.’s pancreatic stem-cell-based islet cell replacement therapy PEC-Direct...

Roche providing improved anti-Her2 bispecific antibody

Dose escalation trails dating back to 2006 have provided severe toxicity for Trion Pharma's/Fresenius' bispecific anti-HER2 x anti-CD3 antibody...

TES Pharma presents new treatment approach towards AKI and NALFD

Italian TES Pharma s.r.l. (Perugia) has presented preclinical results of TES-991 and a backup compound, both enhancers of mitochondrial...

Cancer drug cures orphan disease skin damage

Patients with the incurable cockayne syndrome suffer from dwarfism, neurological impairment, premature aging and a shortened life span. In 80% of...

Foundation launches £30m award

The Big Beat Challenge will bring together world-leading researchers and innovators to identify and solve any of the biggest problems in heart and...

Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics

Under the terms of the agreement Oxurion will have an exclusive option to license the heparanase inhibitor programmes developed for the...

Novo Nordisk joins Evotec as drug discovery partner

The companies announced that they will also seek to find drug candidates to treat co-morbidities such as diabetic kidney disease, nonalcoholic...